TATRC Tech-Watch Weekly
A weekly collection of COVID-19 focused Telemedicine articles, emerging technologies, clinical guidelines, and workflows from across industry, academia, medical research, and government. Brought to you by the USAMRDC's Telemedicine & Advanced Technology Research Center.
Week of May 31-June 6, 2020
This webcast series engages a panel of critical care experts who will address questions from non-ICU clinicians caring for critically ill patients during the COVID-19 pandemic. Participants are encouraged to ask about any related topics at the time of registration or live during the session.
MORGANTOWN, W.VA. – The West Virginia University Rockefeller Neuroscience Institute (RNI) and WVU Medicine, in conjunction with Oura Health, have addressed a major concern regarding the spread of COVID-19. The RNI has created a digital platform that can detect COVID-19 related symptoms up to three days before they show up.
Dive into the stats and data on all things relative to COVID-19. Explore metrics from asthma risk factors to national spending on healthcare services.
The COVID-19 pandemic has transformed the landscape of ambulatory care with rapid shifts to telehealth. Well-resourced hospitals have quickly made the transition. Community health centers (CHCs), which serve more than 28 million low-income and disproportionately uninsured patients in rural and underserved urban areas of the United States, have not fared as well since ambulatory visits have disappeared, resulting in furloughs, layoffs, and more than 1,900 temporary site closures throughout the country.
A combination of escalating costs, an aging population, and rising chronic health-care conditions that account for 75% of the nation’s health-care costs paint a bleak picture of the current state of American health care. In 2018, national health expenditures grew to $3.6 trillion and accounted for 17.7% of GDP.
There’s a lot of confusion about which medical products might work to prevent or treat coronavirus disease 2019 (COVID-19). Scientists are working hard to develop a number of potential drugs for the prevention or treatment of coronavirus, but none are currently approved by the FDA for these purposes.
The views, opinions and/or findings contained in these articles are those of the author and do not necessarily reflect the views of the Department of Defense and should not be construed as an official DoD/Army position, policy or decision unless so designated by other documentation. No official endorsement should be made. Reference herein to any specific commercial products, process, or service by trade name, trademark, manufacturer, or otherwise, does not necessarily constitute or imply its endorsement, recommendation, or favoring by the U.S. Government.